ALT
NASDAQ
$2.82
Altimmune Inc (ALT)
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $15.45 (+447.87%)
Market Cap
$374M
Free Cash Flow Yield
-18.08%
Beta (5Y)
1.53
Price Chart
Valuation
Market Cap$374M
Forward P/E8.18
PEG32.62
P/S10694.01
P/B1.93
Profitability
Total Revenue (TTM)$41K
Gross Profit (TTM)-$66M
EBITDA-$94M
Operating Margin-111127%
EPS-$0.96
Financial Health
Debt-to-Equity15.2%
Free Cash Flow Yield-18.08%
Growth & Risk
EPS 5Y CAGR-10.93%
Revenue 5Y CAGR-65.33%
FCF 5Y CAGR+14.29%
Beta (5Y)1.53
Sharpe Ratio-0.23